0
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged between €400m and €500m per programme including upfront and milestone payments. Und the deal with the South-Korean Chong Kun Dang Pharm (CKD), Synaffix will provide access to its proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect and HydraSpace, in combination with an undisclosed toxSYN linker-payload, to develop an ADC portfolio against a single cancer target.
Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone…